We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Encysive Pharmaceuticals announced it has received the formal decision letter from the European Commission granting marketing authorization for Thelin (sitaxentan sodium) 100-mg tablets.
The FDA issued a second approvable letter for a treatment for gout, febuxostat, developed by TAP Pharmaceutical Products, a joint venture of Abbott Laboratories and Takeda Pharmaceutical.
Genentech announced that the FDA has notified the company that additional information recently requested during the review of the supplemental biologics license application (sBLA) for Herceptin for the treatment of patients with early-stage, HER2-positive breast cancer has been deemed a major amendment.
Athersys has received approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase I study of ATHX-105, its lead obesity drug candidate.
Merck announced interim data from an ongoing trial of its candidate drug MK-0518 showing that the drug, as part of combination therapy, achieved a comparable viral load reduction to Bristol-Myers Squibb's efavirenz combination in HIV patients.
Following a review of the preliminary data from the Phase II trial of its breast cancer vaccine PX 104.1, Pharmexa has decided to stop recruitment of new patients.
Advancis Pharmaceutical has announced that its Amoxicillin PULSYS Phase III trial for the treatment of adults and adolescents with pharyngitis/tonsillitis due to Group A streptococcal infections (commonly referred to as strep throat) achieved desired microbiological and clinical endpoints.
Genzyme has filed in Europe to expand the CE mark for Synvisc (hylan G-F 20) to include treatment of pain due to osteoarthritis of the ankle and shoulder.